US12605454B2 - Modified CMV VLPs as Vaccine Platform
Summary
USPTO granted Patent US12605454B2 to SAIBA AG for modified Cucumber Mosaic Virus (CMV) virus-like particles (VLPs) incorporating Th cell epitopes for enhanced immune responses as a vaccine platform. The 23-claim patent covers linking antigens to modified CMV VLPs to generate antibody responses. CPC classifications span infectious diseases, autoimmune conditions, metabolic disorders, and neurological applications. The patent application (17714307) was filed April 6, 2022.
What changed
USPTO issued Patent US12605454B2 to SAIBA AG, granting exclusive rights to modified Cucumber Mosaic Virus virus-like particle compositions incorporating Th cell epitopes for vaccine platform applications. The patent covers compositions where universal Th cell epitopes enhance immune responses against linked antigens.
For entities developing vaccine technologies or viral vector platforms, this patent establishes intellectual property boundaries around CMV VLP-based vaccine compositions with T-helper cell epitope enhancements. Technology developers and biotech firms working with plant virus-derived VLPs should conduct freedom-to-operate analyses to assess potential overlap with these claims.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Modified virus-like particles of CMV
Grant US12605454B2 Kind: B2 Apr 21, 2026
Assignee
SAIBA AG
Inventors
Martin Bachmann, Andris Zeltins, Paul Pumpens
Abstract
The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.
CPC Classifications
A61K 47/646 A61K 39/0005 A61K 39/0006 A61K 39/0007 A61K 39/0008 A61K 39/015 A61K 39/08 A61K 39/12 A61K 39/145 A61K 39/155 A61K 39/35 A61K 39/39 A61K 2039/5258 A61K 2039/55561 A61K 2039/575 A61K 2039/6031 A61K 2039/6037 A61K 2039/6075 A61K 2039/6087 A61K 2039/627 C07K 14/005 C07K 14/33 C07K 14/7051 C07K 2319/00 C07K 2319/40 C07K 2319/55 C07K 2319/74 C07K 14/08 C07K 14/54 C07K 14/5409 C07K 14/5437 C12N 7/00 C12N 2760/16034 C12N 2760/16122 C12N 2760/16134 C12N 2760/16171 C12N 2760/18522 C12N 2760/18534 C12N 2770/14022 C12N 2770/14023 A61P 25/06 A61P 25/16 A61P 25/28 A61P 3/10 A61P 5/28 A61P 29/00 A61P 31/14 A61P 31/16 A61P 33/06 A61P 37/02 A61P 37/08 Y02A 50/30
Filing Date
2022-04-06
Application No.
17714307
Claims
23
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.